Neumora plans clinical trials, data readouts through 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Big Stock Moves on NLRP3 Competitive Landscape News; Positive Read-throughs for Neumora Therapeutics (NMRA) - Mizuho
January 7, 2026 1:20 PM ESTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $6.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comets "NMRA shares are +25-30 intraday (vs. +3% XBI) and +50% (vs. +5% XBI) over the past two trading sessions, following we believe recent media... More
